Michael Carrel - Axonics Independent Chairman of the Board
| 0I3 Stock | EUR 63.50 0.00 0.00% |
Chairman
Michael Carrel is Independent Chairman of the Board of Axonics since 2020.
| Age | 48 |
| Tenure | 4 years |
| Phone | 949 396 6322 |
| Web | https://www.axonics.com |
Michael Carrel Latest Insider Activity
Tracking and analyzing the buying and selling activities of Michael Carrel against Axonics stock is an integral part of due diligence when investing in Axonics. Michael Carrel insider activity provides valuable insight into whether Axonics is net buyers or sellers over its current business cycle. Note, Axonics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Axonics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Michael Carrel over three months ago Disposition of 3000 shares by Michael Carrel of AtriCure subject to Rule 16b-3 | ||
Michael Carrel over six months ago Disposition of 500 shares by Michael Carrel of Axonics Modulation subject to Rule 16b-3 |
Axonics Management Efficiency
The company has return on total asset (ROA) of (0.0624) % which means that it has lost $0.0624 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.1453) %, meaning that it generated substantial loss on money invested by shareholders. Axonics' management efficiency ratios could be used to measure how well Axonics manages its routine affairs as well as how well it operates its assets and liabilities.Axonics has accumulated 10.01 M in total debt with debt to equity ratio (D/E) of 0.02, which may suggest the company is not taking enough advantage from borrowing. Axonics has a current ratio of 13.35, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Axonics until it has trouble settling it off, either with new capital or with free cash flow. So, Axonics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Axonics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Axonics to invest in growth at high rates of return. When we think about Axonics' use of debt, we should always consider it together with cash and equity.
Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation systems. Axonics, Inc. was incorporated in 2012 and is headquartered in Irvine, California. AXONICS INC operates under Medical Devices classification in Germany and is traded on Frankfurt Stock Exchange. It employs 416 people. Axonics (0I3) is traded on Frankfurt Exchange in Germany and employs 517 people. Management Performance
| Return On Equity | -0.15 | |||
| Return On Asset | -0.0624 |
Axonics Leadership Team
Elected by the shareholders, the Axonics' board of directors comprises two types of representatives: Axonics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Axonics. The board's role is to monitor Axonics' management team and ensure that shareholders' interests are well served. Axonics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Axonics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Erik Amble, Independent Director | ||
| Jane Kiernan, Independent Director | ||
| MD MAS, Chief Officer | ||
| Raymond Cohen, Chief Executive Officer, Director | ||
| Karen Noblett, Chief Medical Officer | ||
| JD Esq, Gen VP | ||
| John Woock, Chief Marketing Officer | ||
| Neil Bhalodkar, VP Relations | ||
| Nancy Snyderman, Independent Director | ||
| Robert McNamara, Independent Director | ||
| Alfred Ford, Chief Commercial Officer | ||
| Michael Carrel, Independent Chairman of the Board | ||
| Dan Dearen, President, Chief Financial Officer | ||
| Danny Dearen, Pres CFO | ||
| Rinda Sama, Chief Operating Officer | ||
| Juliet Bakker, Independent Director | ||
| Aaron Pettit, G Officer | ||
| David Demski, Director | ||
| Prabodh Mathur, Chief Product Development Officer | ||
| Guangqiang Jiang, Chief Technology Officer |
Axonics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Axonics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.15 | |||
| Return On Asset | -0.0624 | |||
| Profit Margin | (0.31) % | |||
| Operating Margin | (0.25) % | |||
| Current Valuation | 2.7 B | |||
| Shares Outstanding | 49.53 M | |||
| Shares Owned By Insiders | 0.80 % | |||
| Shares Owned By Institutions | 99.20 % | |||
| Price To Book | 5.99 X | |||
| Price To Sales | 11.31 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Axonics Stock
Axonics financial ratios help investors to determine whether Axonics Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Axonics with respect to the benefits of owning Axonics security.